secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001104659-25-086442
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

TransCode shareholders elect directors and approve stock plan increase at 2025 annual meeting
--------------------------------------------------------------------------------

- Elected directors Philippe Calais, Thomas Fitzgerald, Erik Manting, Magda Marquet; each received >84K votes for.
- Approved amendment to 2021 stock plan increasing authorized shares by 166,724; 76,322 for, 18,310 against, 1,434 abstained.
- Ratified WithumSmith+Brown as auditor for FY2025: 301,629 for, 7,844 against, 2,810 abstain; no broker non-votes.
- Adjournment proposal passed but not needed because sufficient votes existed for the stock plan amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925086442/0001104659-25-086442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925086442/tm2524724d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-086442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer